SLC5A2 and heart failure: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as empagliflozin and dapagliflozin, decrease cardiovascular mortality and hospitalizations related to heart failure with reduced LV ejection fraction (98).